If the merger of Pfizer’s off-patent drug unit and Mylan is approved, Mylan CEO Heather Bresch could earn more than $37.6 million in severance and vested benefits, according to The Pittsburgh Post ...

Pfizer will merge its off-patent drug business with generic drugmaker Mylan, a move that would create a lower-priced medication powerhouse, according to The Wall Street Journal. The combined company ...

Viatris Inc. investors can’t proceed with a lawsuit claiming the drugmaker misrepresented its commitment to its biosimilars business segment, the Third Circuit said Thursday.

NEW YORK -- The FDA issued a warning to patients about the EpiPen on Tuesday. In a news release, FDA said EpiPen manufacturers Pfizer and Mylan sent a letter to health care providers noting the EpiPen ...

Viatris (VTRS) shares recorded modest gains in the premarket on Thursday after the Xanax maker exceeded Street forecasts with ...

Viatris on Thursday beat Wall Street estimates for third-quarter results, driven by strong demand for its branded drugs in China and emerging markets, and raised its forecasts for 2025 profit and ...

PITTSBURGH — Mylan has launched a generic drug for fungal infections, the company said Tuesday. Mylan announced the launch, through subsidiary Mylan Pharmaceuticals, of voriconazole tablets in the ...

NEW YORK--(BUSINESS WIRE)--Nussbaum Law Group, P.C. and Roberts Law Firm US, PC: A proposed settlement (“Settlement”) has been reached in a class action lawsuit alleging that Mylan N.V., Mylan ...

Beginning in 2020, Upjohn began managing Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan ...